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Many examples of a successful application of plant-
based expression systems for production of biologi-
cally active recombinant proteins exist in the literature. 
These systems can function as inexpensive platforms for 
the large scale production of recombinant pharmaceuti-
cals or subunit vaccines. Hemagglutinin (HA) is a major 
surface antigen of the influenza virus, thus it is in the 
centre of interests of various subunit vaccine engineer-
ing programs. Large scale production of recombinant 
HA in traditional expression systems, such as mamma-
lian or insect cells, besides other limitations, is expen-
sive and time-consuming. These difficulties stimulate 
an ever-increasing interest in plant-based production of 
this recombinant protein. Over the last few years many 
successful cases of HA production in plants, using both 
transient and stable expression systems have been re-
ported. Various forms of recombinant HA, including 
monomers, trimers, virus like particles (VLPs) or chimeric 
proteins containing its fusion with other polypeptides 
were obtained and shown to maintain a proper anti-
genicity. Immunizations of animals (mice, ferrets, rabbits 
or chickens) with some of these plant-derived hemag-
glutinin variants were performed, and their effectiveness 
in induction of immunological response and protection 
against lethal challenge with influenza virus demonstrat-
ed. Plant-produced recombinant subunit vaccines and 
plant-made VLPs were successfully tested in clinical trials 
(Phase I and II) that confirmed their tolerance and immu-
nogenicity.
Key words: recombinant hemagglutinin, avian influenza, plant-pro-
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INTRODUCTION
Currently licensed influenza vaccines are produced in 
embryonated chicken eggs. For many decades these vac-
cines have been successfully used and proven to be safe 
and effective. Their production system has some limita-
tions, such as a need for specific pathogen-free (spf) em-
bryonated eggs, time needed for  adaptation to the new 
circulating virus subtypes, long production time, and lim-
ited capacity (Cummings et al., 2014). These limitations 
became evident when swine H1N1 influenza pandemic 
emerged unexpectedly, while the main attention was fo-
cused on the H5N1 virus. It is now obvious that there 
is a great demand for development of new technologies 
to engineer recombinant vaccines with capacity for easy 
scaling up and rapid production. Taking into account the 
high mortality rate of poultry caused by highly patho-
genic avian influenza virus H5N1, the necessity of flock 
elimination and resulting economic losses, effective and 
inexpensive vaccines intended not only for humans but 
also animals are needed. Many countries develop alterna-
tive platforms for production of large amounts of safe 
influenza vaccines based on mammalian (Vero, MDCK), 
chicken (CEF), insect (Sf9) or bacterial (Escherichia coli) 
cells (Kanagarajan et al., 2012; www.who.int). However, 
production of subunit vaccines on a large scale using 
these systems is still expensive and unprofitable.
Plant-based expression systems offer several advantag-
es, such as time and cost efficiency, lower risk of con-
tamination from human pathogen and greater scalability 
in comparison to the conventional systems (Obembe 
et al., 2011). They can be divided into two main types, 
stable and transient (Fig. 1). In stable transformants, 
transgenes are incorporated into either the nuclear ge-
nome (transgenic plants) or the chloroplast genome 
(transplastomic plants) (Obembe et al., 2011). A major 
advantage of stably transformed plants is that the het-
erologous protein production is heritable, which allows 
simple and rapid scaling-up. However, relatively long 
time (1–2 years) is required to obtain stabilized transfor-
mants, and often the production level of recombinant 
proteins might be lower than expected. The most popu-
lar method of creating stable transformants is based on 
Agrobacterium-mediated transformation.
Transient expression systems may be used not only 
for quick validation of the plant  expression cassettes but 
also for production of considerable amounts of recombi-
nant proteins within a short time. Transient expression 
systems can be based on: (i) infiltration of plants with 
Agrobacterium carrying a binary vector, (ii) infection of 
plants with a modified plant virus or (iii) combination of 
both, the viral vector-based expression and Agrobacterium-
mediated method (e.g. MagnICON® and ‘Launch vector’ 
system). All variants of transient expression systems are 
much faster than the stable transformation. 
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The growing interest in vaccines against influenza vi-
rus resulted in intensification of work focusing on pro-
duction of the virus antigens in plant-based systems. 
Two surface proteins of influenza viruses, hemagglutinin 
(HA) and neuraminidase (NA), are the primary antigens 
that elicit immunological response after infection. HA is 
considered to be a stronger antigen than NA, thus it is 
the main object of interest for researchers working on 
recombinant vaccines against influenza. HA is synthe-
sized as a precursor polypeptide HA0 in the endoplas-
mic reticulum, where it is assembled into trimers. Then, 
via the Golgi network it is exported to the cell surface 
where it is cleaved by host proteases into two subunits: 
HA1 and HA2. The HA1 subunit forms a globular head 
which contains the receptor binding site, a main target 
for neutralizing antibodies (Stevens et al., 2006). 
The overall scheme of experiments related to the 
production of subunit vaccines against influenza in 
plant-based systems is explained in Fig. 2. Various 
experimental strategies were used to improve the ex-
pression of HA in plants and to enhance the immu-
nogenicity of the plant-produced variants of HA. As 
it is schematically shown in Fig. 3, these strategies can 
be divided into those dependent and independent on 
the plant expression system. The first group includes 
modifications of elements of the expression cassettes 
(mainly in plasmid vectors), improvement of the yield 
of amplification and facilitation of handling (mainly in 
virus-based vectors). The second group includes modi-
fications of the target sequences leading to increased 
translation (due to codon optimization) or increased 
protein accumulation (due to different truncated or 
elongated variants or due to a different subcellular lo-
cation). 
Below, we shortly discuss published reports on suc-
cessful HA production in plant systems listed in Table 1. 
We describe several most promising transient and stable 
systems used for this purpose, next we refer the strat-
egies used for antigenic protein purification and finally, 
we focus on the clinical trials of plant-based vaccine for-
mulations.
TRANSIENT EXPRESSION
Several kinds of transient expression systems were 
used for efficient production of influenza virus antigens. 
In all of them Agrobacterium was either infiltrated using a 
syringe (without a needle), into the underside of leaves 
or vacuum infiltrated using the whole plant. The second 
method, more efficient and convenient, is usually used 
for a large scale production. Nicotiana benthamiana plants 
are routinely used for transient expression.
‘Launch vector’ system
This advanced transient expression system combines 
the elements of plant RNA viral vectors (based on to-
bacco mosaic virus, TMV) and Agrobacterium binary 
plasmids. The system was developed by a group from 
Fraunhofer USA Center for Molecular Biotechnolo-
gy. The hybrid launch vector, pBID4, contains the 35S 
promoter from a cauliflower mosaic virus (35S CaMV) 
that drives initial transcription of the recombinant viral 
genome, the nos terminator, genes for virus replication 
and cell-to-cell movement protein, and the target gene 
cloned under the transcriptional control of the coat pro-
tein subgenomic mRNA promoter. Following agroinfil-
tration, multiple copies of the viral vector sequences are 
produced (replicated) within the plant cells. The cloned 
target genes are then amplified along with the viral se-
quences and they are expressed from multiple copies 
(Musiychuk et al., 2007).
This system was used for production of HA ecto-
domain from different influenza virus strains: H3N2 (A/
Wyoming/03/03), H5N1 (A/Indonesia/05/05), H5N1 
A/Bar-headed Goose/Qinghai/1A/05 and H5N1 A/
Anhui/1/05 (Shoji et al., 2009a; Shoji et al., 2009b; Sho-
ji et al., 2008). The sequences were optimized for plant 
Figure 1. Comparison of two main types of plant expression systems.
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expression and were encoding the truncated HA with-
out the transmembrane domain but with endoplasmic 
reticulum retention signal (KDEL) and the polyhistidine 
affinity purification tag (6xHis) at the C-terminus. The 
native signal peptide was either removed or replaced 
by the PR-1a (tobacco pathogenesis-related protein) 
signal peptide. The yield of HA production was differ-
ent depending on HA subtype, for example the highest 
level of HA H3 achieved on the seventh day post-in-
filtration was 200 mg/kg of tobacco leaves FW. West-
ern blot analysis indicated that HA was produced as an 
intact (uncleaved) monomer. Following confirmation of 
its antigenicity by ELISA and a single-radial immunodif-
fusion (SRID) assay, immunization of Balb/c mice was 
performed. Recombinant antigens along with Quil A (sa-
ponin-based adjuvant) were injected subcutaneously in 
three doses, two weeks apart. The vaccine induced both, 
humoral (HA specific IgG) and cellular (IFNγ and in-
terleukin 5) immune responses (Shoji et al., 2008). The 
sera of mice immunized even with the lowest dose of re-
combinant HA H3 (5 µg) gave positive results in hemag-
glutination inhibition (HI) and virus neutralization (VN) 
tests with the homologous H3N2 influenza virus (Shoji 
et al., 2008). Similarly, all Balb/c mice and 70% of fer-
rets immunized with H5 HA (A/Indonesia/05/05) elic-
ited serum HI antibodies already after the second dose. 
Moreover, immunized ferrets were fully protected against 
challenge with the homologous virus (Shoji et al., 2009a). 
Cross-clade HI antibody reactivity was evaluated by anal-
ysis of sera collected from mice groups immunized with 
either HA H5 from clade 2.2 (A/Bar-headed Goose/
Qinghai/1A/05) or clade 2.3 (A/Anhui/1/05). Both re-
combinant HA variants elicited reciprocal cross-clade re-
activity, while serum HI antibodies against clade 1 (A/
Vietnam/1194/04) and clade 2.1 (A/Indonesia/05/05) 
were not detected (Shoji et al., 2009b).
Similar experiments were done with HAs from the 
strains comprising the 2008–2009 seasonal vaccine 
(A/Brisbane/10/07, A/Brisbane/59/07 and B/Flori-
da/04/06) and California/04/09 (H1N1) (Shoji et al., 
2012). Depending on the HA variant, the level of re-
combinant proteins reached 400-1300 mg/kg FW, and 
the solubility was >70%. The recombinant HA (HAC1) 
from California/04/09 (H1N1) was used as a vaccine 
along with a silica nanoparticle-based (SiO2) drug deliv-
ery system and/or mucosal adjuvant candidate bis-(3’,5’)-
cyclic dimeric guanosine monophosphate (c-di-GMP). 
Mice were immunized by intratracheal route. Interesting-
ly, the double-adjuvanted vaccine induced high system-
ic antibody responses, which were similar to the ones 
induced by the control systemic vaccination (intraperi-
toneally) with HAC1 adsorbed on aluminum hydroxide 
(Alum) (Neuhaus et al., 2014). 
Recent improvement of the expression systems re-
sulted in production of HA antigen in a trimeric form, 
which might mimic the native HA structure (Shoji et al., 
2013). This should enhance immunogenicity and increase 
stability of the recombinant protein. Trimeric forms of 
HA (tHA-BC) from A/California/04/09 strain were 
generated by introducing the trimerization motif from 
an actin binding protein, coronin, at the C-terminus 
of HA. Immunization of mice with this antigen in the 
presence of adjuvant Alhydrogel® (aluminium hydroxide 
gel) induced specific anti-HA neutralizing antibodies and 
protected mice against a lethal dose of mouse-adapted 
A/California/04/09 (MA-CA/04/09) virus used in the 
challenge experiment. As expected, immunogenic and 
protective doses of the trimeric form (tHA-BC) were 
lower than those reported earlier for the monomeric HA 
(HAC1).
This production system was also used to generate fu-
sions consisting of recombinant HA and a carrier mol-
ecule, an engineered enzyme lichenase (LicKM). The 
LicKM enzyme is derived from the thermostable en-
zyme, β-1,3-1,4-glucanase from Clostridium thermocellum 
and was used previously as a carrier molecule for report-
Figure 2. Scheme explaining production of recombinant vaccines in plants. HI, hemagglutinin inhibition; ELISA, enzyme linked im-
munosorbent assay; VN, virus neutralization; SHR, single radial hemolysis; MN, microneutralisation.
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er gene expression in prokaryotic and eukaryotic systems 
(Goldenkova et al., 2002). The LicKM enhanced expres-
sion of recombinant proteins and could be used for easy 
and cost-effective recovery of the target protein. It was 
reported that 10-min heat treatment at 65oC removes up 
to 50% of contaminating plant proteins while leaving 
LicKM fusions unaffected (Musiychuk et al., 2007). The 
launch vector/lichenase carrier system has been applied 
for efficient production of many recombinant variants 
of HA proteins. These fusion proteins include LicKM-
H5SD and LicKM-H5GD containing the stem domain, 
SD (17-58 aa followed by a triple glycine linker and 
293-535 aa), and the globular domain, GD (59-292 aa) 
of HA from A/Vietnam/04 H5N1 virus, respectively, as 
internal fusion with LicKM. 
The expressed HA fusions were recognized by serum 
raised against HA from the A/Vietnam/04 influenza vi-
rus (Musiychuk et al., 2007). Production and evaluation 
of HA domains (SD and GD) of influenza virus A/Wy-
oming/03/03 strain expressed as fusions to the LicKM 
was also reported (Mett et al., 2008). Additionally, one 
NA domain (38-468 aa) was expressed. In all constructs 
the signal peptide of PR1a and 6xHis plus KDEL motif 
were included at the N-terminus and C-terminus, respec-
tively. Production level was about 100 mg/kg FW in the 
case of LicKM-SD and LicKM-GD, whereas for NA it 
was higher (300 mg/kg FW). The plant-produced HA-
LicKM fusion was highly immunogenic and protected 
immunized ferrets against infection with a homologous 
virus. Enhancement of the immune response in ferrets 
was observed after addition of recombinant NA (Mett et 
al., 2008).
MagnICON® system
Plant transient expression system — MagnICON® 
(ICON Genetics GmbH, Halle, Germany) is based on 
in planta assembly of functional viral vectors from two 
separate 5’ and 3’ pro-vector modules. Agrobacterium 
cells are used to deliver various modules that are subse-
quently assembled inside the plant cells with the help of 
a site-specific recombinase (Marillonnet et al., 2004, Gle-
ba et al., 2005). Thus, the system combines advantages 
of Agrobacterium-mediated transfection (high efficiency) 
with the high speed and expression level of viral vectors.
This system was used to obtain HA-based vaccine for 
chickens against H5N1. The full-length H5 HA from 
the reassortant virus strain NIBRG-14 was targeted to 
different cell compartments like cytoplasm, chloroplast 
and apoplast (Kalthoff et al., 2010). The highest level of 
recombinant protein (300 mg/kg FW) was achieved in 
the case of apoplast targeting, especially when the signal 
peptide of tobacco calreticulin was used. Recombinant 
HA was highly immunogenic and its application with ad-
juvant fully protected chickens against a lethal challenge 
infection with heterologous H5N1 (A/whooper swan/
Germany/R65/2006) virus. 
The MagnICON® system has been used also by our 
group. The aim was to obtain an efficient production 
of the recombinant HA1 subunit of HA (17-338 aa) 
Figure 3. Plant-based HA expression strategies discussed in this work.
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from H5N1 (A/swan/Poland/305-135V08/2006) vi-
rus. The recombinant protein was targeted either to ap-
oplast (HA1APO) or to ER (HA1ER) and contained a 
His-tags. In both cases higher than expected molecular 
weight of the recombinant protein was observed, due to 
N-glycosylation. The proteins were partially purified by 
affinity chromatography using Ni NTA agarose under 
native or denaturing conditions. The highest amount of 
purified HA1 was obtained for HA1ER purified under 
native condition, (3.33 mg/kg FW), while the amount 
of HA1APO was about four times lower (0.83 mg/kg 
FW) (Fig. 4). Reactivity of purified HA with monoclonal 
anti-HA (H5N1) antibody purified from hybridoma cells 
(Mab 6-9-1, Institute of Biotechnology and Antibiotics, 
Warsaw, Poland) was tested by ELISA using Ni-NTA 
HisSorb Strips which allow antigen immobilization on 
the well surface by His-tag that, in turn, leads to a uni-
form orientation of the His-tagged antigens. The ELISA 
results confirmed specific interaction of plant-produced 
HA1 with anti-HA H5N1 antibody. We would like to 
emphasize that the applied method allows fast and effi-
cient production of HA and/or its fragments, which can 
be applied for characterization and detection of anti-HA 
antibodies, for example to replace the Escherichia coli-pro-
duced proteins in such devices as electrochemical immu-
nosensors (Jarocka et al., 2014).
Comparable results were reported by another group 
(Spitsin et al., 2009). In either stable or transient sys-
tems they obtained various versions of HA from H5N1 
(A/Vietnam/1203/2004), including the full-length HA 
(1–549 aa), a shorter version containing only major an-
tigenic domains (1–330 aa) either alone or 
in a fusion with Fc (human or mouse), a 
version truncated at C-terminal part (1–277 
aa) and the same version additionally lacking 
the N-terminal region (68–277aa). The pro-
duction level of HA1-Fc in MagnICON® 
system was about 1 mg/kg FW. Howev-
er, after purification by protein-A (affinity) 
chromatography the yield decreased by 50%. 
Interestingly, although significant humoral 
immune responses were observed in mice 
immunized with various HA1 variants, none 
of them induced virus-neutralizing (VN) an-
tibodies.
Alfalfa plastocyjanin gene expression 
cassette
This system is based on an expression cas-
sette containing upstream and downstream 
regulatory elements of the alfalfa plastocy-
anin gene, namely its promoter and termi-
nator, and its 5’- and 3’-UTRs (D’Aoust et 
al., 2008). The strategy described below led 
to generation of recombinant VLPs in this 
system. The sequences encoding either full-
length H5 HA from the pandemic H5N1 
(A/Indonesia/5/05) virus or the full-length 
H1 HA from the seasonal H1N1 (A/
New Calzedonia/20/99) were cloned into 
the plastocyanin-based expression cassette 
(D’Aoust et al., 2008). In H5-based construct 
the native signal peptide was used, while in 
H1-based one it was replaced by the signal 
peptide from the disulphide isomerase from 
alfalfa. Additionally, the plasmid carrying se-
quence encoding matrix protein M1 from 
H1N1 (A/Puerto Rico/8/34) was co-infil-
trated along with HA constructs in order to 
facilitate the formation of VLPs. Interestingly, transmis-
sion electron microscopy confirmed formation of VLPs 
in extracts from plants agroinfiltrated with HA con-
structs alone, while co-expression of HA and M1 led to 
undesirable results with a substantial decrease of HA ac-
cumulation. The VLPs were located in apoplastic inden-
tations of the plasma membrane. Immunization of mice 
with two doses of 0.1 µg of purified H5-VLPs along 
with Alhydrogel® (adjuvant) induced a strong immune 
response against a homologous virus, whereas two high-
er doses (0.5 µg) protected against a lethal challenge with 
the heterologous strain of H5N1 (A/Vietnam/1194/04). 
The pEAQ vector series 
This system is based on full-length or deleted versions 
of a Cowpea mosaic virus (CPMV) RNA-2, permitting 
efficient and rapid production of protein without viral 
replication (Sainsbury et al., 2009). A series of small bi-
nary vectors, named pEAQ, which may be used for the 
production of a wide variety of protein in both, transient 
and stable expression systems, were engineered. These 
vectors contain 35S CaMV promoter, nopaline synthase 
(nos) terminator, P19 sequence encoding suppressor of 
silencing, and 5’- and 3’-UTRs from CPMV RNA-2. 
The gene of interest is inserted between the UTRs. A 
new generation vector, pCPMV-HT, provides extreme-
ly high translational efficiency and, consequently, a high 
production level of the recombinant protein (Peyret & 
Lomonossoff, 2013).
Figure 4. Expression of HA1 in plants. 
(A) Schematic diagram of the HA1subunit cloned into 3’ provector module. (B) 
Detection of HA1APO and HA1ER in Nicotiana benthamiana leaves by Western 
blot using monoclonal anti-polyHistidine antibody (mouse IgG, Sigma). Protein 
extracts from plant samples collected on selected days as indicated (6-8 dpi); 
K(-) extract from plants infiltrated with buffer. (C) De-glycosylation of HAER. 
Purified HAER were digested with Endo H (New England Biolabs) and PNGase 
(New England Biolabs), separated on SDS PAGE and detected by Western blot 
analysis with monoclonal anti-polyHistidine antibody. Lines 1–3, Endo H-, undi-
gested, PNGase-digested HAER, respectively. M- pre-stained molecular marker 
(Thermo Scientific).
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This system was chosen for industrial-scale (com-
mercial) production of H5 VLPs. The co-expression of 
suppressor silencing or other helper proteins (HSP40 
and HSP70) also significantly increased, especially in the 
case of H3 from H3N2 (A/Brisbane/10/07 H3N2), the 
VLPs accumulation (D’Aoust et al., 2010).
This system was also used for production of a biologi-
cally active full-length HA from H7N7 low pathogenicity 
avian influenza (LPAI) virus isolated from wild Swedish 
mallard ducks (Kanagarajan et al., 2012). Recombinant 
H7 HA was targeted to ER and the yield of production 
was about 200 mg of purified protein per kg of FW.
STABLE EXPRESSION
Stable plant expression systems are used less often for 
the production of recombinant HA (Table 1). To achieve 
the high expression levels, the expression cassettes with 
strong promoters and regulatory elements enhancing 
transcription and translation are used. For example, a se-
ries of pTRA binary vectors containing 35S CaMV pro-
moter with duplicated transcriptional enhancer, chalcone 
synthase 5’ untranslated region (CHS UTR) and 35S 
CaMV polyadenylation signal (pA35S) have been created. 
Additionally, in pTRA vectors two copies of the scaffold 
attachment region (SAR) from tobacco Rb7 (root spe-
cific gene) flank the expression cassette. Another exam-
ple of a series of plant expression vectors is the Impact 
vector™ system created by Plant Research International 
of Wageningen University and Research Center. These 
plasmids contain a very strong, light regulated Rubisco 
promoter. Both series of vectors enable targeting of the 
recombinant proteins into different subcellular compart-
ments. 
The pTRA vectors were used to set up the plant-
based platform for influenza vaccine production in 
South Africa (Mortimer et al., 2012). Two recombinant 
variants, namely full-length and truncated form of HA 
from H5N1 (A/Vietnam/1194/2004) were successfully 
produced in different cellular compartments (cytoplasm, 
chloroplast, ER, and apoplastic spaces). The highest pro-
duction level was observed for full-length HA targeted 
to apoplast (640–1440 mg/kg FW), and for truncated 
HA targeted to ER (160–880 mg/kg FW). Both forms 
of protein were purified and used in an immunization 
experiment, resulting in a serum from vaccinated chick-
ens and mice containing specific anti-H5 HA antibody.
Fusion with elastin-like polypeptide (ELP) is supposed 
to increase the yield and improve the purification yield 
(Phan et al., 2013). Both monomeric and trimeric HA 
(ectodomain, 17–520 aa), with and without ELP poly-
peptide, were generated in transgenic N. tabacum plants 
and in transiently transformed N. benthamiana. To gen-
erate the trimeric form of HA, the trimeric motif from 
GCN4-pII was fused to the C terminus of HA ecto-
domain. ELPylation increased accumulation of the re-
combinant HA in plant leaves without influencing the 
functionality and the antigenicity of the HA trimers. Im-
munization of mice indicated that the trimeric form of 
HA induced a higher HA-specific immune response than 
the monomeric form, regardless of the presence or ab-
sence of ELP.
Polypeptide variants of the HA from H5N1 were pro-
duced in MagnICON® system (see above) and in trans-
genic plants using ImpactVector systems (Spitsin et al., 
2009). Interestingly, expression of chimeric protein HA1-
Fc in transgenic plants was 4-fold higher than in tran-
sient system and reached 4 mg/kg FW. In comparison H
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with HA1 alone (without Fc) the overall yield of produc-
tion and purification stage requiring only one step was 
improved, but fusion-related enhancement of the immu-
nogenicity in vaccinated mice was not detected (Spitsin 
et al., 2009).
INTERSPECIFIC NICOTIANA HYBRID
The main disadvantage of Nicotiana sp. plants as bio-
reactors for production of recombinant pharmaceuticals 
is a high concentration of toxic pyridine alkaloids, which 
precludes direct application of the crude plant extract 
or even only partially purified proteins. To get around 
this problem Ling and coworkers (Ling et al., 2012) en-
gineered interspecific Nicotiana hybrid by crossing two 
transgenic lines, Nicotiana tabacum LAFC-HA producing 
recombinant HA and Nicotiana glauca A622-RNAi car-
rying a construct to downregulate alkaloid biosynthesis 
genes. The hybrid plants expressed HA and did not syn-
thesize alkaloids in leaves. Importantly, these plants can 
be easily propagated by vegetative cuttings and did not 
produce viable pollen, which eliminates potential prob-
lems with bio-contamination. The crude extract from hy-
brid plants was used for mice immunization. It appeared 
to be nontoxic and elicited a high HA-specific IgG an-
tibody titer as confirmed by ELISA. Moreover, analysis 
of TNFα (tumor necrosis factor α) and IFNα induction 
after incubation of the peripheral mononuclear cells with 
either purified HA or the crude extracts from the hy-
brid or control plants indicated that the plant extracts 
induced a stronger cytokine production than the purified 
HA (Ling et al., 2012).
PURIFICATION OF RECOMBINANT HA
Over 90% of the total cost of recombinant subunit 
vaccine production is related to the downstream process-
ing, namely the separation and purification steps (Conley 
et al., 2011). Plant-produced recombinant HA has been 
purified by various methods prior to vaccination. The 
first step after plant tissue homogenization was filtra-
tion through Miracloth. Next, if the His-tag was present 
(in most cases), the partial purification by immobilized 
metal affinity chromatography was performed (Spitsin et 
al., 2009; Shoji et al., 2008; Mortimer et al., 2012). Anion 
exchange chromatography (Shoji et al., 2009b; Shoji et al., 
2009a; Mett et al., 2008; Shoji et al., 2012) and ultrafiltra-
tion, followed by diafiltration and filter sterilization with 
a 0.2 µm membrane were also used (Shoji et al., 2011). 
Mortimer and coworkers (Mortimer et al., 2012), be-
sides affinity purification on Ni-NTA resin, applied also 
diafiltration using hollow fiber cartridges with a 50 kDa 
membrane cut off.
The process of selective extraction followed by two-
phase separation and gel filtration was used to pu-
rify full-length HA expressed in a MagnICON® system 
(Kalthoff et al., 2010) while H5-VLPs purification con-
sisted of several steps starting with homogenization and 
centrifugation, followed by a clarification step based on 
chemical and physical treatments. The clarified extract 
was concentrated and stabilized, then the proteins were 
isolated through a series of chromatographic steps in-
cluding ion exchange and affinity chromatography and 
concentrated by cross-flow filtration and sterilized by fil-
tration (D’Aoust et al., 2010).
Recombinant HAs were also expressed as chimeric 
proteins to facilitate purification, as a fusion with Fc 
fragment allowing a single-step purification using protein 
A (Spitsin et al., 2009) or as a fusion with elastin-like pol-
ypeptide (ELP) enabling extraction of the fusion protein 
using membrane-based inverse transition cycling (Phan et 
al., 2013). The second strategy not only improved pro-
tein purification but also reduced its cost. ELP are oligo-
meric repeats of the pentapeptide Val-Pro-Gly-Xaa-Gly 
(where Xaa is any amino acid except Pro) that undergo a 
reversible inverse temperature transition. ELP is mono-
meric and soluble at a temperature below the transition 
temperature (Tt), while it aggregates and becomes insol-
uble at a temperature above Tt. This strategy was used 
to purify monomeric and trimeric HA (Phan et al., 2013).
CLINICAL TRIALS OF PLANT-DERIVED SUBUNIT 
VACCINES AGAINST INFLUENZA VIRUS
Recombinant proteins used in pharmaceutical applica-
tions require certain quality standards. The good manu-
facturing practice (GMP) grade is obligatory for clinical 
purposes. At least two large biomanufacturing facili-
ties are capable of plant-derived HA production under 
GMP conditions, Fraunhofer USA Center for Molecular 
Biotechnology (FhCMB) from USA and Medicago Inc. 
from Canada. 
A large scale production of H1 HA (HAC1) and H5 
HA (HAI-05) from H1N1 (A/California/04/09) and 
H5N1 (A/Indonesia/05/05), respectively, has been re-
ported by the FhCMB group (Shoji et al., 2011). Recom-
binant proteins were produced under GMP conditions 
in N. benthamiana using transient expression strategy 
based on the ‘launch vector’. Physicochemical and im-
munochemical properties of the purified HAC1 (average 
yield 90 mg/kg FW) and HAI-05 (average yield 50 mg/
kg FW) were characterized and their immunogenicity 
and safety was evaluated in pre-clinical studies in mice, 
rabbits and ferrets (Shoji et al., 2011; Chichester et al., 
2012). Subsequently, both subunit vaccines were demon-
strated to be safe and immunogenic in healthy human 
volunteers during Phase I of clinical trials (Chichester et 
al., 2012; Cummings et al., 2014). In both cases vaccine 
was administered intramuscularly, twice at three week in-
tervals, to healthy adults of 18-50 years old. Three doses 
(15, 45 and 90 µg) with or without Alhydrogel® (adju-
vant) were tested. The highest response, detected by HI 
and VN antibody titers, was observed in the group im-
munized with the highest dose (90 µg) without adjuvant.
According to the data deposited on the Medica-
go Inc. website (http://www.medicago.com/) , three 
technologies were developed by the company for pro-
duction of vaccines in the plant systems: (i) the Profi-
cia™ technology based on transient protein expression 
in plant leaves; (ii) Virus-Like Particles (VLPs) and (iii) 
the VLPExpress™ platform that accelerates the discov-
ery and development of new vaccines by rapid expres-
sion, purification and testing of candidate VLPs. Using 
these technologies, Medicago Inc. has successfully pro-
duced H5 HA-based virus-like-particles (VLPs) derived 
from H5N1 (A/Indonesia/5/05) virus in N. benthamiana 
(Landry et al., 2010). Immunogenicity of the HA VLP 
vaccine was confirmed by the HI test, single radial he-
molysis and microneutralisation. In the pre-clinical trials 
the alum adjuvanted plant-made VLPs induced produc-
tion of cross-reactive antibodies in ferrets. In the Phase 
I of clinical trials, healthy adults of 18–60 years old were 
vaccinated intramuscularly twice, 21 days apart, with 
three different doses (5, 10 and 20 µg) of alum-adju-
vanted H5 VLP vaccine or with a placebo. The vaccine 
was well tolerated at all tested doses. Additionally, the 
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immunogenicity of plant-specific glycans was studied in 
humans during these trials and there was no induction 
of antibodies directed against plant N-glycans (Landry 
et al., 2010). Medicago Inc. also successfully expressed 
a new VLP antigen (H1 VLP) based on H1 HA from 
H1N1 influenza virus A using the Company’s VLP vac-
cine and Proficia manufacturing technologies. Recombi-
nant antigen was expressed within 14 days after receiving 
the DNA sequence and induced a positive immune re-
sponse in 100% of the vaccinated animals. Even a sin-
gle dose of 5 µg of HA VLP vaccine was inducing a 
response against the H1N1 (A/California/04/09) virus. 
In June 2011, Medicago completed a Phase I clinical trial 
with the candidate VLP vaccine (“H1N1 vaccine”). All 
doses tested were safe, well tolerated and induced a sol-
id immune response that met the criteria of The Com-
mittee for Medicinal Products for Human Use (CHMP). 
Therefore, Medicago Inc. intends to proceed with a U.S. 
Phase IIa trial for its seasonal trivalent vaccine with an-
tigens from the recommended H1N1, H3N2 and B in-
fluenza strains. The company also completed a Phase II 
clinical trial with the H5 VLP candidate against pandem-
ic flu (H5N1). The candidate vaccine was applied intra-
muscularly or intradermally with Glucopyranosyl lipid A 
and was well tolerated (http://www.medicago.com).
CONCLUSIONS AND PERSPECTIVES
Data published on the WHO website (http://who.int/
immunization/diseases/influenza /clinical_evaluation_ta-
bles/en/.containing) concerning influenza candidate vac-
cines under clinical trials clearly indicate that most of the 
tested candidates for pandemic and potentially pandemic 
vaccines are either inactivated virions, inactivated split vi-
ruses or live attenuated viruses produced in embryonat-
ed eggs or in Vero cells. Only about 5% consist of re-
combinant vaccines produced in SP9 insect cells, chick-
en embryonic fibroblasts (CEF), E. coli and plants. It is 
not surprising, since the egg-based vaccine production is 
the oldest and the best-established technology, while the 
modern systems for production of the second genera-
tion vaccines need more time for recognition. However, 
considering limitations of the egg-based manufacturing 
system and the nature of influenza virus leading to rap-
id emergence of potentially pandemic strains, it is real-
ly important to develop alternative production systems. 
Positive results of the Phase I and Phase II clinical trials 
with plant-derived monomeric HA or VLPs confirmed 
that plant-based production platforms are reliable. Partic-
ularly noteworthy are transient expression systems, espe-
cially in emergency situations, such as pandemics. These 
systems are well established, less controversial (no genet-
ically modified plants involved) and their most important 
advantage is speed. Medicago Corp. announced that it is 
able to produce 10 million doses of H1N1 VLP influen-
za vaccine candidate in one month. In current traditional 
manufacturing technologies that relay on strain adapta-
tion, this period lasts 4–6 months. However, we should 
remember that the traditional vaccines, which are com-
posed of the whole inactivated virus are more immu-
nogenic and only one dose of vaccine is routinely used. 
Thus, reduction of the number of administrated doses 
and development of needle-free, easy to apply routs of 
administration should be the most important challenges 
for these novel technologies. Indeed, combination of the 
short production time with high effectiveness, low dose 
costs and comfort of vaccination would give a competi-
tive advantage to the plant-based vaccines. 
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